Terms: = Prostate cancer AND EPS15, AF-1P, 2060, ENSG00000085832, P42566, MLLT5, AF1P AND Treatment
18 results:
1. Regional differences in penile cancer patient characteristics and treatment rates across the United States.
Scheipner L; Cano Garcia C; Barletta F; Incesu RB; Morra S; Baudo A; Assad A; Tian Z; Saad F; Shariat SF; Chun FKH; Briganti A; Tilki D; Longo N; Carmignani L; Leitsmann M; Ahyai S; Karakiewicz PI
Cancer Epidemiol; 2023 Oct; 86():102424. PubMed ID: 37506474
[TBL] [Abstract] [Full Text] [Related]
2. Salvage Retzius-Sparing Radical prostatectomy: A Review of Complications, Functional Outcomes, and Oncologic Outcomes.
Mason JB; Hatch L; Dall C; Kowalczyk KJ
Curr Oncol; 2022 Dec; 29(12):9733-9743. PubMed ID: 36547178
[TBL] [Abstract] [Full Text] [Related]
3. Simulation model of disease incidence driven by diagnostic activity.
Westerberg M; Larsson R; Holmberg L; Stattin P; Garmo H
Stat Med; 2021 Feb; 40(5):1172-1188. PubMed ID: 33241594
[TBL] [Abstract] [Full Text] [Related]
4. Management of Climacturia During Inflatable Penile Prosthesis Surgery.
El-Khatib FM; Towe M; Choi J; Yafi FA
Curr Urol Rep; 2019 Feb; 20(4):16. PubMed ID: 30806828
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Basis of Drug Resistance and Insights for New treatment Approaches in mCRPC.
Giacinti S; Poti G; Roberto M; Macrini S; Bassanelli M; DI Pietro F; Aschelter AM; Ceribelli A; Ruggeri EM; Marchetti P
Anticancer Res; 2018 Nov; 38(11):6029-6039. PubMed ID: 30396917
[TBL] [Abstract] [Full Text] [Related]
6. Transurethral ultrasound therapy of the prostate in the presence of calcifications: A simulation study.
Suomi V; Treeby B; Jaros J; Makela P; Anttinen M; Saunavaara J; Sainio T; Kiviniemi A; Blanco R
Med Phys; 2018 Nov; 45(11):4793-4805. PubMed ID: 30216469
[TBL] [Abstract] [Full Text] [Related]
7. The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy.
Mazzola R; Fersino S; Fiorentino A; Ricchetti F; Giaj Levra N; Di Paola G; Sicignano G; Naccarato S; Ruggieri R; Alongi F
Clin Transl Oncol; 2016 Mar; 18(3):317-21. PubMed ID: 26250766
[TBL] [Abstract] [Full Text] [Related]
8. NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer.
Berlin A; Lalonde E; Sykes J; Zafarana G; Chu KC; Ramnarine VR; Ishkanian A; Sendorek DH; Pasic I; Lam WL; Jurisica I; van der Kwast T; Milosevic M; Boutros PC; Bristow RG
Oncotarget; 2014 Nov; 5(22):11081-90. PubMed ID: 25415046
[TBL] [Abstract] [Full Text] [Related]
9. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
Jespersen CG; Nørgaard M; Borre M
Eur Urol; 2014 Apr; 65(4):704-9. PubMed ID: 23433805
[TBL] [Abstract] [Full Text] [Related]
10. Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy.
Yoon M; Ahn SH; Kim J; Shin DH; Park SY; Lee SB; Shin KH; Cho KH
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1477-85. PubMed ID: 19879701
[TBL] [Abstract] [Full Text] [Related]
11. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.
Lee WR; Bae K; Lawton C; Gillin M; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H
Cancer; 2007 Apr; 109(8):1506-12. PubMed ID: 17340591
[TBL] [Abstract] [Full Text] [Related]
12. Dietary agents in the chemoprevention of prostate cancer.
Shukla S; Gupta S
Nutr Cancer; 2005; 53(1):18-32. PubMed ID: 16351503
[TBL] [Abstract] [Full Text] [Related]
13. Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NF kappa B.
Vayalil PK; Mittal A; Katiyar SK
Carcinogenesis; 2004 Jun; 25(6):987-95. PubMed ID: 14742313
[TBL] [Abstract] [Full Text] [Related]
14. Antiandrogen-induced cell death in LNCaP human prostate cancer cells.
Lee EC; Zhan P; Schallhom R; Packman K; Tenniswood M
Cell Death Differ; 2003 Jul; 10(7):761-71. PubMed ID: 12815459
[TBL] [Abstract] [Full Text] [Related]
15. [The clinical value of PSA and ECT in diagnosis of prostate cancer bone metastasis].
Ma HQ; Ge JP; Wei W; Gao JP
Zhonghua Nan Ke Xue; 2002; 8(4):289-91. PubMed ID: 12491698
[TBL] [Abstract] [Full Text] [Related]
16. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Arah IN; Dixon SC; Horti J; Figg WD
Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
[TBL] [Abstract] [Full Text] [Related]
17. Antimüllerian hormone in patients with hypogonadotropic hypogonadism.
Young J; Rey R; Couzinet B; Chanson P; Josso N; Schaison G
J Clin Endocrinol Metab; 1999 Aug; 84(8):2696-9. PubMed ID: 10443662
[TBL] [Abstract] [Full Text] [Related]
18. High-precision conformal radiotherapy (HPCRT) of prostate cancer--a new technique for exact positioning of the prostate at the time of treatment.
Bergström P; Löfroth PO; Widmark A
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):305-11. PubMed ID: 9788408
[TBL] [Abstract] [Full Text] [Related]
